SYNCOM FORMULATIONS (INDIA)
Back to Balance Sheet
|
SYNCOM FORMULATIONS (INDIA) Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2017 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹12 Cr | ₹10.00 Cr | ₹8.66 Cr | ₹7.76 Cr | ₹7.73 Cr |
What is the latest Total Non-Current Liabilities ratio of SYNCOM FORMULATIONS (INDIA) ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹12 Cr |
| Mar2024 | ₹10.00 Cr |
| Mar2023 | ₹8.66 Cr |
| Mar2022 | ₹7.76 Cr |
| Mar2017 | ₹7.73 Cr |
How is Total Non-Current Liabilities of SYNCOM FORMULATIONS (INDIA) Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹12 Cr | 18.16 | |
| Mar2024 | ₹10.00 Cr | 15.49 | |
| Mar2023 | ₹8.66 Cr | 11.53 | |
| Mar2022 | ₹7.76 Cr | 0.36 | |
| Mar2017 | ₹7.73 Cr | - | |
Compare Total Non-Current Liabilities of peers of SYNCOM FORMULATIONS (INDIA)
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SYNCOM FORMULATIONS (INDIA) | ₹1,273.7 Cr | 4.2% | -3.1% | -26.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹406,615.0 Cr | 4% | -4.9% | -2.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹159,943.0 Cr | 1.1% | -9.3% | 9.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹133,336.0 Cr | -1.3% | -3.7% | 24% | Stock Analytics | |
| CIPLA | ₹107,499.0 Cr | 1.5% | -9.3% | -7.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,590.0 Cr | 5% | -0.1% | 3.3% | Stock Analytics | |
SYNCOM FORMULATIONS (INDIA) Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SYNCOM FORMULATIONS (INDIA) | 4.2% |
-3.1% |
-26.1% |
| SENSEX | 3.5% |
-1.7% |
7.8% |
You may also like the below Video Courses